TD Private Client Wealth LLC Grows Position in Fresenius Medical Care AG & Co. KGaA $FMS

TD Private Client Wealth LLC raised its stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 6,380.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,925 shares of the company’s stock after purchasing an additional 4,849 shares during the period. TD Private Client Wealth LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $141,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Fifth Third Bancorp lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 156.6% during the second quarter. Fifth Third Bancorp now owns 19,654 shares of the company’s stock worth $562,000 after purchasing an additional 11,994 shares during the period. Park Avenue Securities LLC acquired a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter worth $256,000. Millennium Management LLC lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 50.0% during the first quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock worth $26,982,000 after purchasing an additional 361,364 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 14.2% during the first quarter. AQR Capital Management LLC now owns 14,297 shares of the company’s stock worth $356,000 after purchasing an additional 1,777 shares during the period. Finally, Advisors Asset Management Inc. lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 243.3% during the first quarter. Advisors Asset Management Inc. now owns 7,817 shares of the company’s stock worth $195,000 after purchasing an additional 5,540 shares during the period. 8.37% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on FMS shares. Zacks Research cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. Wall Street Zen cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 5th. Finally, UBS Group reiterated a “sell” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, September 2nd. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $27.80.

Fresenius Medical Care AG & Co. KGaA Trading Up 1.4%

Shares of FMS stock opened at $25.56 on Monday. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 0.44. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $18.94 and a fifty-two week high of $30.46. The stock’s fifty day moving average price is $25.23 and its two-hundred day moving average price is $26.08.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.02. The company had revenue of $5.54 billion for the quarter, compared to the consensus estimate of $5 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%. On average, equities analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current year.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.